Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Epigenetic analysis of Li-Fraumeni Syndrome cancers for identification of novel mechanisms of tumorigenesis in cancer susceptibility
EF 2013-14
Résumé
Approximately 2 in 5 Canadians will develop cancer in their lifetime and 1 in 4 Canadians will die of cancer. It is now well known that human cancers are caused by abnormal changes in the genetic make-up of cells. However, other abnormal events in cells have recently been shown to contribute to the development of cancer. One of these additional abnormal events involves chemical changes that do not directly affect the genetic make-up. These indirect changes are known as epigenetic modifications.
Our research aims to better understand non-genetic causes of cancer by exploring the role of epigenetic modifications. To achieve this, our lab studies patients who have a rare but classic inherited syndrome that increases their risk of developing cancer: Li-Fraumeni Syndrome (LFS). People with LFS have a 90% chance of developing cancer in their lifetime and most develop devastating tumors in childhood and early adulthood. These include brain tumors, bone cancers and early breast cancers, among other tumor types. Some, but not all, patients with LFS have an inherited defect in a gene known as TP53. Our research aims to understand if epigenetic modifications play a role in what type of cancer LFS patients develop and when these tumors are predicted form in the patient's lifetime. This critical research question has not yet been answered.
This work will lead to a better overall understanding of cancer because TP53 is a gene that is defected in many cancers, including those that are not inherited. Since epigenetic modifications have been detected in many human cancers, we anticipate to find changes in LFS patients with TP53 defects and those without TP53 defects. We hope to use clinical data from patients with LFS that we tested for epigenetic modifications to see if we can make clinical predictions for patients with this disease. Finally, this research will help reveal new cellular processes that control how inherited defects actually lead to cancer.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
300304
Name
Samuel Nardin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Epigenetic analysis of Li-Fraumeni Syndrome cancers for identification of novel mechanisms of tumorigenesis in cancer susceptibility
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer Genetics; Cancer Susceptibility; Genomics; Germline Tp53 Mutations; Li-Fraumeni Syndrome; Methylation; Microarray; Sequencing; Tumor Suppressors
Abstract
Approximately 2 in 5 Canadians will develop cancer in their lifetime and 1 in 4 Canadians will die of cancer. It is now well known that human cancers are caused by abnormal changes in the genetic make-up of cells. However, other abnormal events in cells have recently been shown to contribute to the development of cancer. One of these additional abnormal events involves chemical changes that do not directly affect the genetic make-up. These indirect changes are known as epigenetic modifications.
Our research aims to better understand non-genetic causes of cancer by exploring the role of epigenetic modifications. To achieve this, our lab studies patients who have a rare but classic inherited syndrome that increases their risk of developing cancer: Li-Fraumeni Syndrome (LFS). People with LFS have a 90% chance of developing cancer in their lifetime and most develop devastating tumors in childhood and early adulthood. These include brain tumors, bone cancers and early breast cancers, among other tumor types. Some, but not all, patients with LFS have an inherited defect in a gene known as TP53. Our research aims to understand if epigenetic modifications play a role in what type of cancer LFS patients develop and when these tumors are predicted form in the patient's lifetime. This critical research question has not yet been answered.
This work will lead to a better overall understanding of cancer because TP53 is a gene that is defected in many cancers, including those that are not inherited. Since epigenetic modifications have been detected in many human cancers, we anticipate to find changes in LFS patients with TP53 defects and those without TP53 defects. We hope to use clinical data from patients with LFS that we tested for epigenetic modifications to see if we can make clinical predictions for patients with this disease. Finally, this research will help reveal new cellular processes that control how inherited defects actually lead to cancer.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Samuel, Nardin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~